Is AstraZeneca Abbott's most likely merger partner?
This article was originally published in Scrip
Executive Summary
Following the announcement on 19 October that Abbott Laboratories is to separate its prescription pharmaceutical unit from its other business units, speculation has turned to whether a rival big pharma player will make a move to acquire Abbott’s prescription portfolio, which is heavily focused on the anti-TNF biologic therapy Humira (Scripintelligence.com 20 October 2011).